<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395473</url>
  </required_header>
  <id_info>
    <org_study_id>0653-087</org_study_id>
    <secondary_id>2006_041</secondary_id>
    <nct_id>NCT00395473</nct_id>
  </id_info>
  <brief_title>Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)</brief_title>
  <official_title>Ezetimibe Added to Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      In the context of australian general practice, to determine the efficacy and safety of
      ezetimibe 10mg/statin 40mg coadministration in patients with uncontrolled cholesterol
      receiving statin 40mg or more.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) reduction in plasma low-density lipoprotein cholesterol (ldl-c) concentration after 6 weeks of treatment</measure>
  </primary_outcome>
  <enrollment type="Actual">141</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0653, ezetimibe / Duration of Treatment: 6 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will remain on a stable statin dose of 40mg or more, for the duration of
             the study

          -  Patients with coronary heart disease or diabetes mellitus whose cholesterol levels
             remain above the initial threshold for government subsidy after at least 3 months of
             treatment at a daily dose of 40mg or greater of a statin

        Exclusion Criteria:

          -  Illnesses such as congestive heart failure nyha class iii or iv

          -  Uncontrolled hypertension

          -  Myocardial infarction

          -  Coronary bypass surgery or angioplasty with or without stent within 3 months of the
             enrolment visit

          -  Unstable angina pectoris or unstable or severe peripheral vascular disease

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins, ex: type i or type ii diabetes mellitus that is poorly controlled

          -  Serum creatinine &gt;0.18mmol/l at enrolment or active renal disease with significant
             proteinuria

          -  Disorders of the haematologic, digestive (including malabsorptive disorders)

          -  Central nervous system including cerebrovascular disease and degenerative diseases
             that would limit study evaluation or participation

          -  Active acute or chronic hepatobiliary disease

          -  Patients taking the following medication: medications known to interact with statin
             medication including antifungal azoles, macrolide antibiotics, telithromycin;
             nefazodone; protease inhibitors; amiodarone; danazol and verapamil; fibrates;
             cyclosporin

          -  Tg &gt;4.0mmol/l while using a statin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Simons LA, Symons J. Ezetimibe added to statin therapy (EASY study) - an evaluation by Australian general practitioners. Aust Fam Physician. 2007 Jan-Feb;36(1-2):90-2, 96.</citation>
    <PMID>17252094</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2006</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

